Zentalis Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Zentalis Pharmaceuticals

08/05/2024 14:32

* Zentalis Pharmaceuticals Inc  ZNTL.OQ  reported quarterly
adjusted earnings of 14 cents​​ per share for the quarter ended
in March, higher than the same quarter last year, when the
company reported EPS of $-1.07.  The mean expectation of
ten analysts for the quarter was for a loss of 77 cents per
share. Wall Street expected results to range from -96 cents
to -39 cents per share.
    * Revenue was $40.56 million​; analysts expected $13.13
million. 
    * Zentalis Pharmaceuticals Inc's reported EPS for the
quarter was
14 cents​.
    * The company reported quarterly net income of $10.07
million.
    * Zentalis Pharmaceuticals Inc shares had fallen by 21.9%
this
quarter and lost 18.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 12.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Zentalis
Pharmaceuticals Inc is $35.00 

This summary was machine generated from LSEG data May 8 at 01:32
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.77          0.14           Beat
 Dec. 31 2023      -0.92          -0.93          Missed
 Sep. 30 2023      -0.91          -0.79          Beat
 Jun. 30 2023      -1.04          -1.85          Missed